Presentation at The Kempen & Co Life Sciences Conference

SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

May 12, 2021SynAct Pharma partners with Örebro University to study cardiovascular disease
May 12, 2021SynAct Pharma ingår samarbete med Örebro universitet för att studera hjärt-kärlsjukdomar
May 5, 2021SynAct Pharma: Interim report January-March 2021
May 5, 2021SynAct Pharma: Delårsrapport januari-mars 2021

All press releases

News

April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
October 28, 2019Redeye: Adding an indication

Donation to Reumatikerförbundet

Calendar

May 21, 2021Annual general Meeting 2021 / Årsstämma 2021
May 25, 2021ABGSC Life Science Summit
August 27, 2021Interim report Q2 2021

Subscribe to our press releases